Posted by Michael Wonder on 17 Aug 2023
AbbVie announces European Commission approval of Aquipta (atogepant) for the preventive treatment of migraine in adults
17 August 2023 - Approval is based on two pivotal Phase 3 studies that demonstrated statistically significant reduction in mean monthly migraine days with Aquipta compared to placebo in adult patients with both chronic and episodic migraine.
AbbVie today announced that the European Commission has approved Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month.
